Search

Search Constraints

You searched for: Author/Creator Stoelzel, Matthias

Search Results

1. A strategy utilizing ambulatory monitoring and home and clinic blood pressure measurements to optimize the safety evaluation of noncardiovascular drugs with potential for hemodynamic effects: a report from the SYNERGY trial. Issue 3 (June 2018)

2. Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add‐on mirabegron therapy to solifenacin (BESIDE). Issue 5 (16th April 2017)

3. Cardiovascular Safety of the β3‐Adrenoceptor Agonist Mirabegron and the Antimuscarinic Agent Solifenacin in the SYNERGY Trial. (12th April 2018)

4. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study). (8th June 2017)

6. Long‐term treatment of older patients with overactive bladder using a combination of mirabegron and solifenacin: a prespecified analysis from the randomized, phase III SYNERGY II study. Issue 2 (15th January 2019)

7. Patient‐reported outcomes from SYNERGY, a randomized, double‐blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with monotherapy and placebo in OAB patients. Issue 1 (13th July 2017)

8. Vasomotor symptoms, sleep problems, and depressive symptoms in community‐dwelling Japanese women. Issue 10 (18th July 2021)